Eli Lilly, Compounders and drug Zepbound

US judge ruling for FDA bars copies of Lilly weight loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. The decision was filed late on Wednesday in response to an October lawsuit from a compounding industry group against the U.
Compounders must stop making copies of Eli Lilly’s weight loss drugs: Judge
Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.
Court denying compounders’ motion positive for Eli Lilly, says Morgan Stanley
Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
US judge denies injunction, restricting copies of Lilly weight-loss drug
By Patrick Wingrove and Brendan Pierson (Reuters) - A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs.
Fierce Pharma2h
With Eli Lilly flying high, CEO David Ricks collects 10% pay bump to $29.2M
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Modern Healthcare4d
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Fierce Pharma3d
Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Verywell Health on MSN9d
Eli Lilly Lowers Cost of Zepbound Vials to Attract People Without Insurance Coverage
Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...
Fierce Biotech12d
Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
Fierce Healthcare2d
Eli Lilly expands telehealth access to low-cost Zepbound with Teladoc Health, LifeMD tie-ups
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Eli Lilly (NYSE:LLY) Achieves Breakthrough Efficacy With EBGLYSS for Atopic Dermatitis in Long-Term Study
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.